HeartSciences (HSCS) Change in Receivables (2022 - 2025)

HeartSciences (HSCS) reported Change in Receivables of -$4350.0 for Q3 2025, down 200.0% quarter-over-quarter from $4350.0 in Q2 2025.

HeartSciences (HSCS) Change in Receivables (2022 - 2025) Analysis & Trends

HeartSciences has reported Change in Receivables for 3 years, with the latest figure at -$4350.0 in Q3 2025.

For the quarter ending Q3 2025, Change in Receivables changed N/A year-over-year to -$4350.0; the trailing twelve-month figure through Oct 2025 stood at $10800.0 (changed N/A YoY), and the FY2025 full-year result was $4350.0, changed N/A from the prior year.
Change in Receivables for Q3 2025 stood at -$4350.0, down from $4350.0 in the prior quarter.
The five-year high for Change in Receivables was $10800.0 in Q1 2024, with the low at -$4350.0 in Q3 2025.
Historically, Change in Receivables has averaged $2119.8 across 3 years, with a median of $1014.5 in 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	42.00 Mn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	-444.00 Mn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	-13.00 Mn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	117.00 Mn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	117.90 Mn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	-
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-124.60 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	-141.00 Mn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	123.50 Mn
10	HeartSciences	3.89 Mn	492,884.20	-	-

Download Data